Sandoz Biopharma Head Levick To Become CEO Of Alvotech
Mark Levick, Sandoz’ head of development for biopharmaceuticals, has been chosen to become CEO of Alvotech from August.
You may also be interested in...
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
Alvotech has brought in a Pfizer biosimilars specialist as chief scientific officer, while Lupin has recruited a women’s health expert to head its US Specialty business. And Ian Read is to retire as Pfizer’s chairman at the start of next year.
Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.